Response to comment on "Speciation analysis of gadolinium chelates in hospital effluents and wastewater treatment plant sewage by a novel HILIC/ICP-MS method"

Environmental Science and Technology

Volumn 43, Issue 14, 2009, Pages 5549-5550

  Künnemeyer, Jens ^a   Terborg, Lydia ^a   Meermann, Björn ^a   Brauckmann, Christine ^a   Möller, Ines ^a   Scheffer, Andy ^a   Karst, Uwe ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM CHELATE;

ANALYSIS; AQUATIC ENVIRONMENT; EFFLUENT; HOSPITAL; LETTER; MASS SPECTROMETRY; SEWAGE; WASTE WATER TREATMENT PLANT; WATER SAMPLING;

EID: 67650422583     PISSN: 0013936X     EISSN: 15205851     Source Type: Journal    
DOI: 10.1021/es901550c     Document Type: Letter

References (11)

1. Künnemeyer, J.; Terborg, L.; Meermann, B.; Brauckmann, C.; Möller, I.; Scheffer, A.; Karst, U. Speciation analysis of gadolinium chelates in hospital effluents and wastewater treatment plant sewage by a novel HILIC/ICP-MS method. Environ. Sci. Technol. 2009, 43, 2884-2890.
2. Kulaksiz, S.; Bau, M. Contrasting behaviour of anthropogenic gadolinium and natural rare earth elements in estuaries and the gadolinium input into the North Sea. Earth Planet. Sci. Lett. 2007, 260, 361-371.
3. Möller, P.; Dulski, P.; Bau, M.; Knappe, A.; Pekdeger, A.; Sommer-von Jarmersted, C. Anthropogenic gadolinium as a conservative tracer in hydrology. J. Geochem. Explor. 2000, 69, 409-414.
4. Puttagunta, N. R.; Gibby, W. A.; Puttagunta, V. L. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. Invest. Radiol. 1996, 31, 619-624.
5. Cowper, S. E.; Robin, H. S.; Steinberg, L. D.; Su, S.; Gupta, P. E. LeBoit, Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000, 356, 1000-1001.
6. Boyd, K. E.; Xiao, Y. Y.; Fan, K.; Poholek, A.; Copeland, N. G.; Jenkins, N. A.; Perkins, A. S. Gadolinium deposition in nephrogenic fibrosis dermopathy. Blood 2006, 107, 733-741.
7. Marckmann, P.; Skov, L.; Rossen, K.; Dupont, A.; Damholt, M. B.; Heaf, J. G.; Thomsen, H. S. Nephrogenic systemic fibrosis: Suspected caustive role of gadodiamide used for contrast-enhanced magnetic resonance imaging. Am. Soc. Nephrol. 2006, 17, 2359-2362.
8. Frenzel, T.; Lengsfeld, P.; Schirmer, H.; Hütter, J.; Weinmann, H.-J. Stability of gadolinium-based magnetic resonance imaging contrast agents inhumanserum. Invest. Radiol. 2008, 43, 817-828.
9. Idee, J. M.; Port, M.; Raynal, I.; Schaefer, M.; Le Greneur, S.; Corot, C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: A review. Fundam. Clin. Pharmacol. 2006, 20, 563-576.
10. Morcos, S. K. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition. Br. J. Radiol. 2007, 80, 73-76.
11. Künnemeyer, J.; Terborg, L.; Nowak, S.; Scheffer, A.; Telgmann, L.; Tokmak, F.; Günsel, A.; Wiesmüller, G.; Reichelt, S.; Karst, U. Speciation analysis of gadolinium-based MRI-contrast agents in blood plasma by hydrophilic interaction chromatography/electrospray mass spectrometry. Anal. Chem. 2008, 80, 8163-8170.